Viable Hemostasis Obtained With Prothrombin Complex Concentrate in Patients Who Refuse Standard Allogeneic Blood Transfusion and Undergo Complex Cardiac Surgery: A Case Series.


Journal

A&A practice
ISSN: 2575-3126
Titre abrégé: A A Pract
Pays: United States
ID NLM: 101714112

Informations de publication

Date de publication:
Jul 2020
Historique:
entrez: 10 9 2020
pubmed: 11 9 2020
medline: 29 7 2021
Statut: ppublish

Résumé

Human 4-factor prothrombin complex concentrate (4F-PCC) may reduce blood loss during surgery. This case series described perioperative outcomes among 9 patients who refused standard allogeneic blood transfusion, underwent complex cardiac surgery with aortic involvement, and received intraoperative 4F-PCC. Additional intraoperative cointerventions included protamine (n = 9), aminocaproic acid (n = 8), fibrinogen concentrate (n = 6), desmopressin (n = 6), factor VIIa (n = 2), and tranexamic acid (n = 1). Outcomes included postoperative death (n = 1), major postoperative bleeding (n = 1), deep vein thrombosis (n = 2), and ischemic stroke (n = 1). When standard allogeneic blood transfusion is refused, viable hemostasis can be obtained using 4F-PCC during complex cardiac surgeries with a high risk of bleeding.

Identifiants

pubmed: 32909724
doi: 10.1213/XAA.0000000000001276
pii: 02054229-202007000-00025
doi:

Substances chimiques

Blood Coagulation Factors 0
prothrombin complex concentrates 37224-63-8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e01276

Références

Chand NK, Subramanya HB, Rao GV. Management of patients who refuse blood transfusion. Indian J Anaesth. 2014; 58:658–664
Totaro P, Carlini S, Pozzi M, et al. Minimally invasive approach for complex cardiac surgery procedures. Ann Thorac Surg. 2009; 88:462–466
Ferraris VA, Brown JR, Despotis GJ, et al. Society of Thoracic Surgeons Blood Conservation Guideline Task Force. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011; 91:944–982
Engelman DT, Ben Ali W, Williams JB, et al. Guidelines for perioperative care in cardiac surgery: enhanced recovery after surgery society recommendations. JAMA Surg. 2019; 154:755–766
Cappabianca G, Mariscalco G, Biancari F, et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Crit Care. 2016; 20:5
Arnékian V, Camous J, Fattal S, Rézaiguia-Delclaux S, Nottin R, Stéphan F. Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interact Cardiovasc Thorac Surg. 2012; 15:382–389
Dyke C, Aronson S, Dietrich W, et al. Universal definition of perioperative bleeding in adult cardiac surgery. J Thorac Cardiovasc Surg. 2014; 147:1458.e1–1463.e1
Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work GroupKDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012; 2:1–138
The Society of Thoracic Surgeons. Adult Cardiac Surgery Database.. Available at: https://www.sts.org/registries-research-center/sts-national-database/adult-cardiac-surgery-database. Accessed December 11, 2019
Harris JE, Varnado S, Herrera E, Salazar E, Colavecchia AC. Evaluation of postoperative clinical outcomes in Jehovah’s Witness patients who receive prothrombin complex concentrate during cardiac surgery. J Card Surg. 2020; 35:801–809
Kcentra (Prothrombin Complex Concentrate (Human)) [package insert]. 2018Kankakee, ILCSL Behring LLC
Goldstein LJ, Davies RR, Rizzo JA, et al. Stroke in surgery of the thoracic aorta: incidence, impact, etiology, and prevention. J Thorac Cardiovasc Surg. 2001; 122:935–945
Martens A, Beckmann E, Kaufeld T, et al. Total aortic arch repair: risk factor analysis and follow-up in 199 patients. Eur J Cardiothorac Surg. 2016; 50:940–948
Matsuura K, Ogino H, Matsuda H, et al. Prediction and incidence of atrial fibrillation after aortic arch repair. Ann Thorac Surg. 2006; 81:514–518
Schwann TA, Kistler L, Engoren MC, Habib RH. Incidence and predictors of postoperative deep vein thrombosis in cardiac surgery in the era of aggressive thromboprophylaxis. Ann Thorac Surg. 2010; 90:760–766

Auteurs

Tomona Iso (T)

From the Department of Pharmacy, Houston Methodist, Houston, Texas.
Department of Pharmacy Research, Houston Methodist Research Institute, Houston, Texas.

Elsie Rizk (E)

From the Department of Pharmacy, Houston Methodist, Houston, Texas.
Department of Pharmacy Research, Houston Methodist Research Institute, Houston, Texas.

Jesse E Harris (JE)

Department of Pharmacy.

Eric Salazar (E)

Department of Pathology and Genomic Medicine.

Kirk Heyne (K)

Department of Oncology.

Elizabeth Herrera (E)

Division of Cardiovascular and Thoracic Anesthesiology, Department of Anesthesiology.

Jessica Varisco (J)

Quality and Patient Safety Department, Houston Methodist Hospital, Houston, Texas.

Joshua T Swan (JT)

From the Department of Pharmacy, Houston Methodist, Houston, Texas.
Department of Surgery, Institute for Academic Medicine.
Center for Outcomes Research, Institute for Academic Medicine, Houston Methodist Research Institute, Houston, Texas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH